← Back to Search

Cell Therapy

Fat Cell Injection for Knee Osteoarthritis (SVF Trial)

Phase < 1
Waitlist Available
Led By Claude T Moorman, MD
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up year 1
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a single injection of a person's own fat cells to treat knee osteoarthritis after an injury.

Who is the study for?
This trial is for adults aged 18-45 who've had significant knee trauma or surgery between 1 and 20 years ago, leading to Post-Trauma Osteoarthritis (PTOA). They should have ongoing knee pain despite trying at least two treatments like medication or physical therapy. Participants need a BMI under 35, speak English, and be able to attend follow-up visits. Pregnant women, tobacco users, those with recent knee injections or certain medical conditions are excluded.
What is being tested?
The trial is testing the safety and feasibility of a single injection of autologous Adipose Derived Stromal Vascular Fraction (SVF) in treating knee PTOA. It's a before-after study conducted at two sites where participants' own processed fat tissue is used to potentially repair their injured knees.
What are the potential side effects?
While specific side effects aren't listed for SVF treatment in this summary, similar procedures may cause pain at the injection site, swelling, infection risk increase and possible allergic reactions to local anesthetics used during the procedure.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~year 1
This trial's timeline: 3 weeks for screening, Varies for treatment, and year 1 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Adverse Events
Other study objectives
General Health scores - Patient-Reported Outcomes Measurement Information System (PROMIS 29)
Knee Pain scores - The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Knee Pain scores - Visual Analog Scale (VAS)
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: a single injection of autologous Adipose Derived (AD) Stromal Vascular Fraction (SVF)Experimental Treatment1 Intervention
a single injection of autologous Adipose Derived (AD) Stromal Vascular Fraction (SVF) for the treatment of knee Post Traumatic Osteoarthritis (PTOA)

Find a Location

Who is running the clinical trial?

Wake Forest University Health SciencesLead Sponsor
1,403 Previous Clinical Trials
2,477,925 Total Patients Enrolled
9 Trials studying Osteoarthritis
914 Patients Enrolled for Osteoarthritis
Claude T Moorman, MDPrincipal InvestigatorWake Forest University Health Sciences

Media Library

Adipose Derived (AD) Stromal Vascular Fraction (SVF) (Cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05515523 — Phase < 1
Osteoarthritis Research Study Groups: a single injection of autologous Adipose Derived (AD) Stromal Vascular Fraction (SVF)
Osteoarthritis Clinical Trial 2023: Adipose Derived (AD) Stromal Vascular Fraction (SVF) Highlights & Side Effects. Trial Name: NCT05515523 — Phase < 1
Adipose Derived (AD) Stromal Vascular Fraction (SVF) (Cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05515523 — Phase < 1
Osteoarthritis Patient Testimony for trial: Trial Name: NCT05515523 — Phase < 1
~7 spots leftby Aug 2025